Avadel Pharmaceuticals plc

NasdaqGM:AVDL Lagerbericht

Marktkapitalisierung: US$1.2b

Avadel Pharmaceuticals Management

Management Kriterienprüfungen 3/4

Wir verfügen derzeit nicht über ausreichende Informationen über den CEO.

Wichtige Informationen

Greg Divis

Geschäftsführender

US$985.2k

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts60.9%
Amtszeit als Geschäftsführer5.7yrs
Eigentum des Geschäftsführersn/a
Durchschnittliche Amtszeit des Managements4.8yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder6.2yrs

Jüngste Management Updates

Recent updates

Health Check: How Prudently Does Avadel Pharmaceuticals (NASDAQ:AVDL) Use Debt?

Sep 10
Health Check: How Prudently Does Avadel Pharmaceuticals (NASDAQ:AVDL) Use Debt?

Avadel Pharmaceuticals: The Oxybate War With Jazz Waxes On

Sep 03

Avadel Pharmaceuticals: Inflection Point Ahead

Jun 16

Avadel Pharmaceuticals: A Deep Dive Into Lumryz's Once-Nightly Revolution

Apr 02

Avadel Pharmaceuticals: Robust Launch Of Lumryz And Eased Litigation Overhang

Mar 05

Avadel Pharmaceuticals: Strong Launch Of Lumryz With A Legal Risk Backdrop

Jan 28

Is Avadel Pharmaceuticals (NASDAQ:AVDL) Weighed On By Its Debt Load?

Jan 16
Is Avadel Pharmaceuticals (NASDAQ:AVDL) Weighed On By Its Debt Load?

Avadel May Continue To Outperform With Positive Launch Momentum

Jan 11

Is Avadel Pharmaceuticals (NASDAQ:AVDL) Using Debt Sensibly?

Sep 22
Is Avadel Pharmaceuticals (NASDAQ:AVDL) Using Debt Sensibly?

Are Investors Undervaluing Avadel Pharmaceuticals plc (NASDAQ:AVDL) By 49%?

Aug 01
Are Investors Undervaluing Avadel Pharmaceuticals plc (NASDAQ:AVDL) By 49%?

Is There An Opportunity With Avadel Pharmaceuticals plc's (NASDAQ:AVDL) 45% Undervaluation?

May 03
Is There An Opportunity With Avadel Pharmaceuticals plc's (NASDAQ:AVDL) 45% Undervaluation?

Avadel Pharmaceuticals filed for 500M mixed shelf offering

Aug 31

Avadel Pharmaceuticals Q2 2022 Earnings Preview

Aug 08

Avadel Pharmaceuticals (NASDAQ:AVDL) Is Carrying A Fair Bit Of Debt

Jul 07
Avadel Pharmaceuticals (NASDAQ:AVDL) Is Carrying A Fair Bit Of Debt

Avadel rises 18% as it expects tentative approval for sleep disorder drug; expects final approval by June 2023

Jun 29

Avadel: Further Delay, But Some Light At The End Of The Tunnel

Jun 16

Avadel Pharmaceuticals Plc: Initiating Buy, Bye Bye To Sleepiness

Mar 21

Health Check: How Prudently Does Avadel Pharmaceuticals (NASDAQ:AVDL) Use Debt?

Mar 15
Health Check: How Prudently Does Avadel Pharmaceuticals (NASDAQ:AVDL) Use Debt?

Health Check: How Prudently Does Avadel Pharmaceuticals (NASDAQ:AVDL) Use Debt?

Nov 19
Health Check: How Prudently Does Avadel Pharmaceuticals (NASDAQ:AVDL) Use Debt?

Avadel Pharmaceuticals: I Am Holding

Nov 01

Avadel Pharmaceuticals, The Jazz-Killer

Aug 05

Is Avadel Pharmaceuticals (NASDAQ:AVDL) Using Debt In A Risky Way?

Jul 23
Is Avadel Pharmaceuticals (NASDAQ:AVDL) Using Debt In A Risky Way?

Avadel presents new clinical data from Phase 3 REST-ON trial of FT218 in narcolepsy

Jun 09

Avadel Pharmaceuticals EPS beats by $0.09

May 10

Need To Know: The Consensus Just Cut Its Avadel Pharmaceuticals plc (NASDAQ:AVDL) Estimates For 2021

Mar 11
Need To Know: The Consensus Just Cut Its Avadel Pharmaceuticals plc (NASDAQ:AVDL) Estimates For 2021

Is Avadel Pharmaceuticals plc (NASDAQ:AVDL) Popular Amongst Institutions?

Feb 05
Is Avadel Pharmaceuticals plc (NASDAQ:AVDL) Popular Amongst Institutions?

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Greg Divis im Vergleich zu den Einnahmen von Avadel Pharmaceuticals verändert?
DatumGesamtvergütungGehaltUnternehmensgewinne
Jun 30 2024n/an/a

-US$106m

Mar 31 2024n/an/a

-US$157m

Dec 31 2023US$985kUS$600k

-US$160m

Sep 30 2023n/an/a

-US$159m

Jun 30 2023n/an/a

-US$143m

Mar 31 2023n/an/a

-US$142m

Dec 31 2022US$754kUS$561k

-US$137m

Sep 30 2022n/an/a

-US$132m

Jun 30 2022n/an/a

-US$134m

Mar 31 2022n/an/a

-US$90m

Dec 31 2021US$3mUS$545k

-US$77m

Sep 30 2021n/an/a

-US$66m

Jun 30 2021n/an/a

-US$56m

Mar 31 2021n/an/a

-US$6m

Dec 31 2020US$3mUS$520k

US$7m

Sep 30 2020n/an/a

US$16m

Jun 30 2020n/an/a

US$18m

Mar 31 2020n/an/a

-US$21m

Dec 31 2019US$1mUS$472k

-US$33m

Sep 30 2019n/an/a

-US$94m

Jun 30 2019n/an/a

-US$101m

Mar 31 2019n/an/a

-US$96m

Dec 31 2018US$685kUS$417k

-US$95m

Sep 30 2018n/an/a

-US$40m

Jun 30 2018n/an/a

-US$2m

Mar 31 2018n/an/a

US$30m

Dec 31 2017US$1mUS$375k

US$68m

Vergütung im Vergleich zum Markt: GregDie Gesamtvergütung ($USD985.20K) liegt unter dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt US ($USD5.64M).

Entschädigung vs. Einkommen: GregDie Bezüge der Mitarbeiter sind gestiegen, während das Unternehmen unrentabel ist.

Geschäftsführer

Greg Divis (57 yo)

5.7yrs

Amtszeit

US$985,200

Vergütung

Mr. Gregory J. Divis Jr., also known as Greg, has been Director of Avadel Pharmaceuticals plc since June 3, 2019 and has been its Chief Executive Officer since January 2019. Mr. Divis served as an Interim...

Führungsteam

NamePositionAmtszeitVergütungEigentümerschaft
Gregory Divis
CEO & Director5.7yrsUS$985.20kkeine Daten
Thomas McHugh
Senior VP4.8yrsUS$663.14k0.084%
$ 1.0m
Richard Kim
Chief Commercial Officer3.6yrsUS$770.95k0%
$ 0
Jerad Seurer
General Counsel & Company Secretary4yrskeine Daten0.0091%
$ 111.7k
Gregory Davis
VP of Corporate and Business Development9.2yrskeine Daten0.17%
$ 2.0m
Mark Elrod
Vice President of Sales8.1yrskeine Datenkeine Daten
Angie Woods
Vice President of People & Culture3.3yrskeine Datenkeine Daten
Jordan Dubow
Consultant5.4yrsUS$982.54kkeine Daten
Jason Vaughn
Senior Vice President of Technical Operations4.8yrskeine Datenkeine Daten
Jennifer Gudeman
Senior Vice President of Medical & Clinical Affairsno datakeine Datenkeine Daten

4.8yrs

Durchschnittliche Betriebszugehörigkeit

56yo

Durchschnittliches Alter

Erfahrenes Management: AVDLDas Führungsteam des Unternehmens gilt als erfahren (4.8 Jahre durchschnittliche Betriebszugehörigkeit).

Vorstandsmitglieder

NamePositionAmtszeitVergütungEigentümerschaft
Gregory Divis
CEO & Director5.3yrsUS$985.20kkeine Daten
Jean-Marie Lehn
Member of Scientific Advisory Board19.7yrskeine Datenkeine Daten
Mark McCamish
Independent Director4.8yrsUS$449.84k0.070%
$ 850.5k
Naseem Amin
Independent Directorless than a yearkeine Datenkeine Daten
Peter Thornton
Independent Director7.3yrsUS$459.84k0.086%
$ 1.1m
Christian Trepo
Member of Scientific Advisory Board19.7yrskeine Datenkeine Daten
Patrick Couvreur
Member of Scientific Advisory Boardno datakeine Datenkeine Daten
Eric Ende
Independent Director5.8yrsUS$452.34k0.17%
$ 2.1m
Catherine Bréchignac
Chairman of Scientific Advisory Boardno datakeine Datenkeine Daten
Geoffrey Glass
Independent Non-Executive Chairman of the Board6.2yrsUS$482.34k0.13%
$ 1.6m
Linda Palczuk
Independent Director6.2yrsUS$452.34k0.054%
$ 665.0k

6.2yrs

Durchschnittliche Betriebszugehörigkeit

62yo

Durchschnittliches Alter

Erfahrener Vorstand: AVDLDie Vorstandsmitglieder gelten als erfahren (5.9 Jahre durchschnittliche Amtszeit).